Galera Therapeutics, Inc. (GRTX): Nasdaq/NYSE listing notice — Galera receives Nasdaq delisting notice for failing to meet $50M MVLS; plans appeal

Galera Therapeutics, Inc.

Nasdaq notified Galera on Dec 6, 2022 of failure to regain compliance with $50M MVLS requirement by Dec 5 deadline.
Trading suspension and delisting from Nasdaq Global Market scheduled for Dec 15 unless hearing requested by Dec 13.
Company will request a hearing to appeal; request will stay suspension pending Panel decision.
May seek transfer to Nasdaq Capital Market if Global Market listing is not continued.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Galera Therapeutics, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: market value
Rules: 5450(b)(2)(A)

Exact text from the filing

December 6, 2022, Galera Therapeutics, Inc. (the “Company”) received a letter from the Nasdaq Listing Qualifications staff of The Nasdaq Stock Market (“Nasdaq”) indicating that the Company has not regained compliance with the minimum Market Value of Listed Securities (“MVLS”) of $50,000,000 required for continued listing on The Nasdaq Global Market, as set forth in Nasdaq Listing Rule 5450(b)(2)(A) (the “MVLS Requirement”), and that, unless the Company requests a hearing before a Nasdaq Hearings Panel (“Panel”) to appeal Nasdaq’s delisting determination by 4:00 p.m. Eastern Time on December 13

View on SEC.gov

8 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Galera Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-301791

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.